Dog Treatment For Staph Infection

Staphage Lysate (SPL) is an all natural staphylococcal biologic effective in providing longterm control of a persistent staphylococcal skin infection in dogs, frequently called
recurrent canine pyoderma. SPL stimulates the natural immune system of the dog, thereby
reducing the recurrences of infection and eliminating the need for repetitive use of
antibiotics. Treating recurrent canine pyoderma with round after round of antibiotics can
be frustrating for the veterinarian, onerous and expensive for the dog owner and stressful
for the dog.

What is Staphage Lysate (SPL)

Staphage Lysate (SPL), Staphylococcus Aureus Phage Lysate is a sterile staphylococcal

biologic containing the components of S.aureus; and a bacteriophage. It is manufactured in
the US by Delmont Laboratories and does not contain any chemical preservatives.
It is the only staphylococcal product of its kind approved for canine use that can reduce the
recurrences of infection and stimulate the immune system simultaneously. It is not a shortterm medication but rather designed to help control the skin infection over time.

How Staphage Lysate (SPL) works

SPL is believed to control pyoderma by enhancing the patients immune responses to
staphylococcal species. Over the past 15 years, evidence from dozens of leading
laboratories has shown that humans and animals have an innate immune system that
allows the patient to react within minutes of exposure to several molecules that are present
exclusively in pathogens (bacteria, viruses and fungi). Though these innate immune
reactions are diverse and complex, all of them are initiated, focused and/or sustained by
the patients production of proteins called cytokines. SPL contains several of the most
powerful known stimulators of cytokines, including bacterial DNA, peptidoglycan, and
lipoteichoic acid. Numerous studies with SPL, in both cell culture and animal models, have
shown that SPL rapidly stimulates production of cytokines. SPLs efficacy is believed to be
due to its powerful ability to stimulate cytokines that enhance the patients innate immune
reactions against skin-associated bacteria (including staphylococcal strains) that cause or
exacerbate pyoderma.

When To Use Staphage Lysate (SPL)

SPL is indicated for the treatment of canine pyoderma and related staphylococcal
hypersensitivity, or polymicrobial skin infections with a staphylococcal component.
It is most effective in dogs with a history of recurrent pyoderma. Underlying conditions
should be ruled out including demodicosis, flea allergy dermatitis and hypothyroidism.
In addition, SPL has been shown to be effective in dogs with resistance to multiple
antibiotics.

About Delmont Labs

Who we Are
Delmont Laboratories, Inc. is a privately held
company with its core focus in developing products
that treat staphylococcal skin infection. We are
committed to ongoing research to better
understand and develop treatments for this
condition and to protect dogs from recurrence and
ensuing methicillin-resistant bacteria. Our product
Staphage Lysate (SPL) has proven highly effective
in providing long-term control of this resistant

condition. It is unique in that it is a whole bacterial cell preparation from common virulent
Staph strains that have been solubilized through the use of polyvalent staphylococcal
bacteriophage.
We work collaboratively with veterinarians everywhere who treat staphylococcal skin
infection. Our experience can be a valuable resource. We also provide direct access to a
board certified veterinary dermatologist to answer any questions and guide you through
the treatment process. We recognize the complexity and challenges surrounding diagnosis
and treatment of this condition.

Our History
Staphage Lysate (SPL) was licensed for human use
in 1959 in the United States. The utility of
bacteriophage and the lysates in the treatment of
staphylococcal infections was reported by Robert
Lincoln, MD in 1948. He also recognized that the
staphylococcal phage lysates were particularly
useful in the treatment of immune compromised
patients and patients with chronic skin infections
such as furunculosis and folliculitis.
Dr. Lincoln helped found Lincoln Laboratories that is now known as Delmont Laboratories.
In 1986 Delmont Laboratories applied to the U. S. Department of Agriculture for a
veterinary license for the use of Staphage Lysate (SPL) in the treatment of recurrent
canine pyoderma. (USDA True Name: Staphylococcus aureus Phage Lysate). The USDA
license was issued in 1987. (Note: Staphage Lysate (SPL) is not currently sold for human
use).
Delmont Laboratories has subsequently obtained veterinary licenses in Canada (English
speaking 1992, French speaking 2000) and in Brazil (2001).

Typical evolution of superficial staphylococcal pyoderma in

dogs
Early in the course of allergic disease, many dogs will
have few or no lesions, though itch may be severe.
This dogs abdomen is erythematous and very
pruritic, though secondary infection has not set in
yet.

As inflammation and self-trauma persist, there is

increasing alopecia and erythema, along with the
beginning signs of superficial pyoderma. This dogs
axilla is developing numerous small erythematous
papules suggestive of early infection, though overt
pustules have not yet developed.
As the staphylococcal infection becomes firmly
established, pustules begin to appear, as shown on
this dogs abdomen.

As the infection progresses, the pustules enlarge and

rupture, creating focal crusted lesions and spreading
out to form circular epidermal collarettes.

As the epidermal collarettes heal, they often become

hyperpigmented in the center. Note in this dog many
circular black spots indicating healed former collarettes,
some collarettes in the process of healing, and some that
appear to be just forming. In this case, we can say that the
superficial staphylococcal infection has been present for
some time.

For more information please visit

http://www.delmontlabs.com